EC Number |
Inhibitors |
Structure |
---|
2.7.7.47 | (1R,4R)-4-[3-[(5)-([4-[amino(iminimyl)methyl]phenyl]amino)(carboxylato)methyl]-5-ethoxylphenoxy]-1-methypiperidin-1-ium |
- |
|
2.7.7.47 | (1S,3S,4R)-4-[2-(2-chlorophenoxy)-5,7-dihydroxy-4-oxo-4H-chromen-8-yl]-3-hydroxy-1-methylpiperidin-1-ium |
- |
|
2.7.7.47 | 2-(1-(2-(4-methylpiperazin-1-yl)acetyl)-3-oxopiperazin-2-yl)-N-phenylacetamide |
- |
|
2.7.7.47 | 2-[[4-[[(4R)-3[(3R)-3-azaniumyl]-4-(2-fluorophenyl)butanoyl]-(1,3-thiazolidin-4-yl]formamido]methyl)phenyl]acetate |
- |
|
2.7.7.47 | 9-O-(adenosine-5'-phophoryl)spectinomycin |
product inhibition of ANT(3'')-Ii domain |
|
2.7.7.47 | AMP-CPP |
dead-end inhibition of ANT(3'')-Ii domain |
|
2.7.7.47 | clindamycin |
residues Phe34, Asp60, Arg63, Gln64, Leu68, Glu87, Thr89, Val90 are responsible for positioning clindamycin into the active site |
|
2.7.7.47 | kanamycin A |
dead-end inhibition of ANT(3'')-Ii domain |
|
2.7.7.47 | kanamycin A |
competitive |
|
2.7.7.47 | N-(4-fluorophenyl)-2-(1-(2-(4-methylpiperazin-1-yl)acetyl)-3-oxopiperazin-2-yl)acetamide |
- |
|